In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Daiichi to buy majority of Indian generics giant Ranbaxy

Executive Summary

Daiichi Sankyo is diversifying into the generic drugs industry by acquiring a majority ownership in public Indian company Ranbaxy Laboratories, one of the top ten generics players worldwide. The transaction is valued between $3.4-4.6bn.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Partial Acquisition
    • Payment Includes Cash

Related Companies

Advertisement
UsernamePublicRestriction

Register